kronos-bio
(2)
Yasir Al-Wakeel
Yasir Al-Wakeel is a physician turned biotech operator who in September 2025 became CEO of Vesalius Therapeutics and a CEO-Partner at Flagship Pioneering. Trained as a doctor at Oxford with a theology degree from Cambridge, he spent a decade structuring more than $30 billion in life-science deals before running finance and strategy at companies like Merrimack, Neon Therapeutics and Kronos Bio. At Vesalius he is betting that many common diseases are actually clusters of genetically distinct conditions waiting to be redefined.
Jorge Dimartino
Jorge F. DiMartino, M.D., Ph.D., is Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium, a San Diego-based biotech pioneering targeted protein degradation. A physician-scientist trained in genetics, immunology, and pediatric oncology across UC Berkeley, Cornell, UC San Diego, and Stanford, DiMartino has spent over two decades advancing cancer drugs from bench to bedside. His fingerprints are on three now-marketed therapies: vismodegib, venetoclax, and enasidenib - each a breakthrough in its own right. At Plexium, he oversees clinical programs targeting SMARCA2, IKZF2, CDK2, and CRAF using the company's DELTA Discovery platform, a novel approach to degrading proteins previously considered undruggable.